| Bioactivity | Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis[1]. |
| Invitro | Ozoralizumab (ATN-103; 0-1000 pM; 48 h) 在 L929 细胞细胞毒性试验中具有高 TNFα 中和效力，对人 TNFα 和猴 TNFα 的 KD 值分别为 20.2 pM 和 16.1 pM[1]。 |
| In Vivo | Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 人 TNF 转基因小鼠) 抑制关节炎并降低关节炎评分[1]。 Animal Model: |
| Name | Ozoralizumab |
| CAS | 1167985-17-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ishiwatari-Ogata C, et, al. Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG. Front Immunol. 2022 Feb 22;13:853008. |